| scholarly article | Q13442814 |
| P356 | DOI | 10.1053/GAST.2003.50018 |
| P698 | PubMed publication ID | 12512034 |
| P50 | author | Harvey J. Alter | Q5677307 |
| David E. Kleiner | Q41449492 | ||
| P2093 | author name string | Yoon Park | |
| David Herion | |||
| T Jake Liang | |||
| Marc G Ghany | |||
| Edward Doo | |||
| Jay H Hoofnagle | |||
| Kittichai Promrat | |||
| Farooq Khokar | |||
| P2860 | cites work | Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial | Q27860949 |
| Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group | Q27861083 | ||
| Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups | Q29614459 | ||
| Histological grading and staging of chronic hepatitis | Q29619625 | ||
| Pathogenesis, natural history, treatment, and prevention of hepatitis C. | Q33841882 | ||
| Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study | Q38462606 | ||
| Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial | Q42008293 | ||
| International collaborative study on the second EUROHEP HCV-RNA reference panel | Q42978378 | ||
| Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group | Q42993140 | ||
| Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening | Q42995334 | ||
| Natural course of progression of liver fibrosis in Japanese patients with chronic liver disease type C--a study of 527 patients at one establishment | Q42999252 | ||
| Peginterferon alfa-2a in patients with chronic hepatitis C. | Q43001243 | ||
| Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis | Q43001248 | ||
| Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial | Q43034904 | ||
| Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA. | Q43035145 | ||
| Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group | Q43037170 | ||
| Genotypic analysis of hepatitis C virus in American patients | Q43041871 | ||
| Clinical outcomes after transfusion-associated hepatitis C. | Q44746801 | ||
| The long-term pathological evolution of chronic hepatitis C. | Q44765507 | ||
| Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I | Q45752944 | ||
| Prognosis of chronic hepatitis C: results of a large, prospective cohort study. | Q50856021 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chronic hepatitis | Q62019625 |
| P304 | page(s) | 97-104 | |
| P577 | publication date | 2003-01-01 | |
| P1433 | published in | Gastroenterology | Q4039279 |
| P1476 | title | Progression of fibrosis in chronic hepatitis C. | |
| P478 | volume | 124 |
| Q42985442 | A comparison of the spectrum of chronic hepatitis C virus between Caucasians and African Americans |
| Q27482028 | A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C |
| Q33632714 | A prognostic model for development of significant liver fibrosis in HIV-hepatitis C co-infection |
| Q43292659 | A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C. |
| Q44275568 | A tale of two viruses: hepatitis C in the age of HAART. |
| Q46526864 | Acute expression of hepatitis C core protein in adult mouse liver: Mitochondrial stress and apoptosis |
| Q39943264 | Altered regulation of extrinsic apoptosis pathway in HCV-infected HCC cells enhances susceptibility to mapatumumab-induced apoptosis |
| Q39813695 | An Assessment of the Use of Chimpanzees in Hepatitis C Research Past, Present and Future: 1. Validity of the Chimpanzee Model |
| Q53259889 | An editor's look-back. |
| Q46478751 | Antiretroviral therapy and liver fibrosis in HIV-infected patients with chronic hepatitis C. |
| Q50575168 | Antiviral therapy decreases hepatic venous pressure gradient in patients with chronic hepatitis C and advanced fibrosis. |
| Q35872121 | Assessment of disease progression in patients with transfusion-associated chronic hepatitis C using transient elastography |
| Q35397221 | Assessment of hepatic fibrosis in pediatric cases with hepatitis C virus in Egypt. |
| Q81242937 | Assessment of liver fibrosis: palpate, poke or pulse? |
| Q37135105 | Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. |
| Q36990696 | Biomarkers of hepatic fibrosis, fibrogenesis and genetic pre-disposition pending between fiction and reality |
| Q44131260 | CCL5 mRNA is a marker for early fibrosis in chronic hepatitis C and is regulated by interferon-α therapy and toll-like receptor 3 signalling |
| Q35167113 | CXCL9 and CXCL10 chemokines as predictors of liver fibrosis in a cohort of primarily African-American injection drug users with chronic hepatitis C. |
| Q38654167 | CXCL9-11 polymorphisms are associated with liver fibrosis in patients with chronic hepatitis C: a cross-sectional study |
| Q35938040 | Cell death and cell death responses in liver disease: mechanisms and clinical relevance |
| Q38922441 | Characterization of fibrosis changes in chronic hepatitis C patients after virological cure: A systematic review with meta-analysis |
| Q36410565 | Chronic hepatitis C: treatment of pegylated interferon/ribavirin nonresponders |
| Q28078684 | Clinical Advancements in the Targeted Therapies against Liver Fibrosis. |
| Q26781789 | Clinical Advances in Fibrosis Progression of Chronic Hepatitis B and C |
| Q47108259 | Clinical Evaluation of Terap C Vaccine in Combined Treatment with Interferon and Ribavirin in Patients with Hepatitis C. |
| Q33386956 | Clinical significance of alanine aminotransferase levels and the effect of ursodeoxycholic acid in hemodialysis patients with chronic hepatitis C. |
| Q35689601 | Controversies in the management of hepatitis C patients with advanced fibrosis and cirrhosis. |
| Q43046773 | Correlation between liver fibrosis and inflammation in patients transplanted for HCV liver disease. |
| Q30473375 | Current status of novel antifibrotic therapies in patients with chronic liver disease |
| Q44637681 | Delayed onset of severe hepatitis C-related liver damage following liver transplantation: A matter of concern? |
| Q64075082 | Diabetes Mellitus and Risk of Hepatic Fibrosis/Cirrhosis |
| Q38773241 | Diabetes mellitus in patients with cirrhosis: clinical implications and management |
| Q42984502 | Diabetes mellitus is associated with impaired response to antiviral therapy in chronic hepatitis C infection |
| Q33955210 | Distinct features in natural history and outcomes of acute hepatitis C. |
| Q43041266 | Documented rapid course of hepatic fibrosis between two biopsies in patients coinfected by HIV and HCV despite high CD4 cell count |
| Q37391823 | Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C |
| Q40178123 | Epidemiologic features of 348 children with hepatitis C virus infection over a 30-year period: a nationwide survey in Japan |
| Q34787367 | Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression |
| Q45630794 | Ethnicity and hepatitis C virus infection |
| Q33862153 | Evaluating progression of liver disease from repeat liver biopsies in children with chronic hepatitis C: a retrospective study |
| Q35956072 | Excess mortality rates in a cohort of patients infected with the hepatitis C virus: a prospective study. |
| Q45208870 | Factors influencing the rate of fibrosis progression in chronic hepatitis C. |
| Q42990078 | Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. |
| Q41174486 | Fibrosis Progression in Paired Liver Biopsies from HIV/HCV-Coinfected Patients without Prior Treatment of Hepatitis C. |
| Q40590610 | Fibrosis Progression in Patients With Chronic Hepatitis C Virus Infection. |
| Q35666213 | Fibrosis progression in chronic hepatitis C virus infection |
| Q42999753 | Fibrosis progression in initially mild chronic hepatitis C. |
| Q38207382 | Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies |
| Q39018310 | Fibrosis progression in paired liver biopsies from HIV/HCV co-infected patients. |
| Q46502465 | Fibrosis progression rates between chronic hepatitis B and C patients with elevated alanine aminotransferase levels |
| Q33350754 | Genes and hepatitis C: susceptibility, fibrosis progression and response to treatment. |
| Q35768011 | Genetic Polymorphisms of IL28B and PNPLA3 Are Predictive for HCV Related Rapid Fibrosis Progression and Identify Patients Who Require Urgent Antiviral Treatment with New Regimens |
| Q57160250 | Genetic variation in the interleukin -28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection |
| Q45399020 | Guidelines for the antiviral therapy of hepatitis C virus carriers with normal serum aminotransferase based on platelet counts |
| Q35090634 | HCV and HIV co-infection: mechanisms and management. |
| Q45489050 | HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. |
| Q44922847 | HIV coinfection with hepatitis C and hepatitis B. |
| Q42318165 | HIV-HCV Coinfection |
| Q88109421 | HMGB1 links chronic liver injury to progenitor responses and hepatocarcinogenesis |
| Q39474323 | Hepatic Inflammation May Influence Liver Stiffness Measurements by Transient Elastography in Children and Young Adults. |
| Q45397978 | Hepatic inflammatory cytokine mRNA expression in hepatitis C virus-human immunodeficiency virus co-infection |
| Q36382231 | Hepatitis C -- identifying patients with progressive liver injury |
| Q36750298 | Hepatitis C and HIV. |
| Q30360538 | Hepatitis C virus and metabolic disorder interactions towards liver damage and atherosclerosis. |
| Q40641829 | Hepatitis C virus dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy |
| Q37254259 | Hepatitis C virus induces interleukin-1β (IL-1β)/IL-18 in circulatory and resident liver macrophages. |
| Q26782033 | Hepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antivirals |
| Q35882845 | Hepatitis C: What is the nature of the problem? |
| Q22305832 | Hepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapies |
| Q35882850 | Hepatitis C: who is at risk and how do we identify them? |
| Q33899640 | Hepatocarcinogenesis associated with hepatitis B, delta and C viruses |
| Q37255168 | Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis |
| Q83184796 | Hyaluronic acid and aspartate aminotransferase levels normalized by liver function can reflect sinusoidal impairment in chronic liver disease |
| Q36008985 | Impact of Cryoglobulinemic Syndrome on the Outcome of Chronic Hepatitis C Virus Infection: A 15-Year Prospective Study. |
| Q43925569 | Impact of interferon-alpha therapy on liver fibrosis progression in patients with HBeAg-negative chronic hepatitis B. |
| Q28538020 | Impact of rural residence and health system structure on quality of liver care |
| Q44421358 | Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. |
| Q30893394 | Improvement of predictive models of risk of disease progression in chronic hepatitis C by incorporating longitudinal data |
| Q33706737 | Inducible protein-10 as a predictive marker of antiviral hepatitis C treatment: A systematic review |
| Q34548428 | Inflammatory response of endothelial cells to hepatitis C virus recombinant envelope glycoprotein 2 protein exposure. |
| Q45422773 | Influence of alcohol on the progression of hepatitis C virus infection: a meta-analysis |
| Q42978401 | Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection |
| Q27477981 | Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C |
| Q45415285 | Insulin resistance is not associated with liver fibrosis progression in HIV/hepatitis C virus-coinfected patients |
| Q35197060 | Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. |
| Q36964114 | Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. |
| Q34041429 | Is autoimmune hepatitis a frequent finding among HCV patients with intense interface hepatitis? |
| Q42254437 | Lipidomic profiling of plasma in patients with chronic hepatitis C infection |
| Q27477966 | Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C |
| Q34450720 | Liver stiffness measurement among patients with chronic hepatitis B and C: results from a 5-year prospective study |
| Q45869694 | Liver stiffness measurements to assess progression of fibrosis in HCV-infected patients with inherited bleeding disorders |
| Q36995854 | Management complexities of HIV/hepatitis C virus coinfection in the twenty-first century |
| Q37727164 | Management of nonresponsive hepatitis C. |
| Q90724782 | Mechanisms Underlying Hepatitis C Virus-Associated Hepatic Fibrosis |
| Q89650897 | Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis |
| Q41818715 | Molecular Link between Liver Fibrosis and Hepatocellular Carcinoma |
| Q40039734 | Multiexponential T(2) analyses in a murine model of hepatic fibrosis at 11.7 T MRI. |
| Q50934392 | Natural History of Hepatitis C. |
| Q44637697 | Natural history and risk factors for progression of hepatitis C virus disease and development of hepatocellular cancer before liver transplantation |
| Q80594561 | Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies |
| Q96576884 | New LncRNAs in Chronic Hepatitis C progression: from fibrosis to hepatocellular carcinoma |
| Q33866383 | Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy |
| Q37678998 | Nonalcoholic Fatty Liver Disease: Clinical Features and Pathogenesis |
| Q39215794 | Noninvasive markers for staging fibrosis in chronic delta hepatitis. |
| Q35235447 | Novel biomarker candidates to predict hepatic fibrosis in hepatitis C identified by serum proteomics |
| Q58693934 | Novel magnetic resonance technique for characterizing mesoscale structure of trabecular bone |
| Q55135762 | On beyond staging and grading: Liver biopsy evaluation in a posttreatment world. |
| Q38295819 | Optimal management of patients with chronic hepatitis C and comorbidities. |
| Q27489097 | Pathological evolution of hepatitis C virus-“Healthy carriers” |
| Q36475325 | Patients with chronic hepatitis C undergoing watchful waiting: Exploring trajectories of illness uncertainty and fatigue |
| Q36730760 | Percutaneous liver biopsy in adult haemophiliacs with hepatitis C virus: safety of outpatient procedure and impact of human immunodeficiency virus coinfection on the spectrum of liver disease. |
| Q35149163 | Plasma sphingolipids as potential indicators of hepatic necroinflammation in patients with chronic hepatitis C and normal alanine aminotransferase level |
| Q45974559 | Polymorphism of OAS-1 determines liver fibrosis progression in hepatitis C by reduced ability to inhibit viral replication. |
| Q33618516 | Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. |
| Q34064042 | Predicting clinical outcomes using baseline and follow-up laboratory data from the hepatitis C long-term treatment against cirrhosis trial |
| Q39350754 | Prediction of morbidity and mortality in patients with chronic hepatitis C by non-invasive liver fibrosis models |
| Q27490865 | Predictors of sustained virologic response in hepatitis C genotype 4 : beyond the usual suspects |
| Q37256017 | Prognostic factors for progression of liver structural lesions in chronic hepatitis C patients |
| Q37270537 | Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. |
| Q40229041 | Progression of fibrosis in advanced chronic hepatitis C: evaluation by morphometric image analysis |
| Q35596325 | Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study |
| Q40339820 | Progression of liver fibrosis among injection drug users with chronic hepatitis C. |
| Q33889225 | Rapid development of advanced liver fibrosis after acquisition of hepatitis C infection during primary HIV infection. |
| Q34194979 | Rate of progression of hepatic fibrosis in patients with chronic hepatitis C: results from the HALT-C Trial |
| Q37397022 | Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C. |
| Q42219509 | Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters |
| Q37003049 | Responder Interferon λ Genotypes Are Associated With Higher Risk of Liver Fibrosis in HIV-Hepatitis C Virus Coinfection |
| Q38166445 | Review article: management of chronic hepatitis C in patients with contraindications to anti-viral therapy |
| Q36609890 | Review article: management of patients with chronic hepatitis C virus infection and "normal" alanine aminotransferase activity. |
| Q46967668 | Rho/Rho kinase is a key enzyme system involved in the angiotensin II signaling pathway of liver fibrosis and steatosis |
| Q43596899 | Ribavirin modulates the conversion of human CD4(+) CD25(-) T cell to CD4(+) CD25(+) FOXP3(+) T cell via suppressing interleukin-10-producing regulatory T cell |
| Q27478329 | STEATOSIS IN CHRONIC HEPATITIS C: WHY DOES IT REALLY MATTER? |
| Q50578674 | Safety and efficacy of peginterferon plus ribavirin in patients with chronic hepatitis C and bridging fibrosis or cirrhosis. |
| Q46853359 | Sensitive detection of hepatocellular injury in chronic hepatitis C patients with circulating hepatocyte-derived microRNA-122. |
| Q40246520 | Serum and exosomal miR-122 and miR-199a as a biomarker to predict therapeutic efficacy of hepatitis C patients. |
| Q37157863 | Serum complement C4a and its relation to liver fibrosis in children with chronic hepatitis C. |
| Q27490911 | Silymarin inhibits in vitro T-cell proliferation and cytokine production in hepatitis C virus infection |
| Q34380399 | Similar progression of fibrosis between HIV/HCV-infected and HCV-infected patients: Analysis of paired liver biopsy samples |
| Q39275400 | Soluble inflammatory markers as predictors of liver histological changes in patients with chronic hepatitis C virus infection. |
| Q53601181 | Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection. |
| Q34207037 | Systematic review: identifying patients with chronic hepatitis C in need of early treatment and intensive monitoring--predictors and predictive models of disease progression |
| Q42264411 | Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study |
| Q30463023 | Test-retest repeatability of MR elastography for noninvasive liver fibrosis assessment in hepatitis C |
| Q37518294 | The 2013 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-Infected Koreans |
| Q26781379 | The 2015 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-Infected Koreans |
| Q54217219 | The IL7RA rs6897932 polymorphism is associated with progression of liver fibrosis in patients with chronic hepatitis C: Repeated measurements design. |
| Q43707240 | The economics of treating chronic hepatitis C patients with peginterferon alpha-2a (40 kDa) plus ribavirin presenting with persistently normal aminotransferase. |
| Q35216592 | The history of the "natural history" of hepatitis C (1968-2009). |
| Q36426596 | The insulin-like growth factor axis and risk of liver disease in hepatitis C virus/HIV-co-infected women |
| Q42727267 | The molecular prevalence of viral infections in transplant candidates with bone marrow suppression, shiraz, southern iran, 2010. |
| Q36944050 | The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection |
| Q52384628 | Three variants in the nicotinamide adenine dinucleotide phosphate oxidase complex are associated with HCV-related liver damage. |
| Q36754790 | Tobacco Smoking Is Not Associated With Accelerated Liver Disease in Human Immunodeficiency Virus-Hepatitis C Coinfection: A Longitudinal Cohort Analysis. |
| Q37003642 | Up-regulation of Plasma Hexosylceramide (d18: 1/18: 1) Contributes to Genotype 2 Virus Replication in Chronic Hepatitis C: A 20-Year Cohort Study |
| Q45330154 | Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office |
| Q46715188 | Usefulness of six non-proprietary indirect markers of liver fibrosis in patients with chronic hepatitis C. |
| Q34086980 | Viral hepatitis in HIV infection |
| Q34670502 | Willingness to undergo a repeat liver biopsy among HIV/hepatitis C virus-coinfected and hepatitis C virus-monoinfected patients |
| Q81415779 | [Steatosis during chronic hepatitis C: the role of insulin resistance and viral factors] |
| Q52286337 | [Treatment of hepatitis C and drug addiction: is the development of "clinically significant" fibrosis a good decision-making criterion?]. |
| Q36709022 | p38α inhibits liver fibrogenesis and consequent hepatocarcinogenesis by curtailing accumulation of reactive oxygen species |
Search more.